H1 earnings growth of 26% reflects the success of the Group’s strategy to build a geographically diversified business and the growing weighting towards professional and specialist recruitment and also Temporary/Contract markets. The US acquisition of Pharmaceutical Strategies last year looks well timed given the strengthening of the US$, and the recent acquisition of Rishworth in New Zealand will be meaningfully earnings enhancing and is virtually self-funding. With H1 results tracking
18 Aug 2016
Interims - Tracking ahead of full year forecasts
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Interims - Tracking ahead of full year forecasts
Empresaria Group plc (EMR:LON) | 36.5 0 0.0% | Mkt Cap: 18.2m
- Published:
18 Aug 2016 -
Author:
Ben Thefaut -
Pages:
4
H1 earnings growth of 26% reflects the success of the Group’s strategy to build a geographically diversified business and the growing weighting towards professional and specialist recruitment and also Temporary/Contract markets. The US acquisition of Pharmaceutical Strategies last year looks well timed given the strengthening of the US$, and the recent acquisition of Rishworth in New Zealand will be meaningfully earnings enhancing and is virtually self-funding. With H1 results tracking